Literature DB >> 9823527

Determination of anti-Toxoplasma gondii immunoglobulin G avidity: adaptation to the Vidas system (bioMérieux).

H Pelloux1, E Brun, G Vernet, S Marcillat, M Jolivet, D Guergour, H Fricker-Hidalgo, A Goullier-Fleuret, P Ambroise-Thomas.   

Abstract

The determination of specific anti-Toxoplasma gondii IgG avidity has been proposed to improve the determination of the date of toxoplasmic seroconversion in pregnant women. In this study, we adapted this serological technique to the Vidas system (bioMérieux) using 6 M urea as the dissociating agent. We studied 356 sera, including 42 sequential sera from sero-conversions in pregnant women. Our results show that the test is easy to use, and that an avidity index higher than 0.300 allows the exclusion of a recent infection acquired less than 4 months before serum sampling.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9823527     DOI: 10.1016/s0732-8893(98)00077-7

Source DB:  PubMed          Journal:  Diagn Microbiol Infect Dis        ISSN: 0732-8893            Impact factor:   2.803


  34 in total

1.  Comparison of immulite with vidas for detection of infection in a low-prevalence population of pregnant women in The Netherlands.

Authors:  F Vlaspolder; P Singer; A Smit; R J Diepersloot
Journal:  Clin Diagn Lab Immunol       Date:  2001-05

2.  Intravenous immunoglobulin therapy: confounding effects on serological screening for toxoplasmosis during pregnancy.

Authors:  H Pelloux; H Fricker-Hidalgo; G Brochier; A Goullier-Fleuret; P Ambroise-Thomas
Journal:  J Clin Microbiol       Date:  1999-10       Impact factor: 5.948

3.  Simplified assay for measuring Toxoplasma gondii immunoglobulin G avidity.

Authors:  H E Prince; M Wilson
Journal:  Clin Diagn Lab Immunol       Date:  2001-09

4.  Antenatal screening for hepatitis B and antibodies to Toxoplasma gondii and rubella virus: evaluation of two commercial immunoassay systems.

Authors:  R J Diepersloot; H Dunnewold-Hoekstra; J Kruit-Den Hollander; F Vlaspolder
Journal:  Clin Diagn Lab Immunol       Date:  2001-07

5.  VIDAS test for avidity of Toxoplasma-specific immunoglobulin G for confirmatory testing of pregnant women.

Authors:  Jose G Montoya; Oliver Liesenfeld; Sandra Kinney; Cynthia Press; Jack S Remington
Journal:  J Clin Microbiol       Date:  2002-07       Impact factor: 5.948

6.  European multicenter study of the LIAISON automated diagnostic system for determination of Toxoplasma gondii-specific immunoglobulin G (IgG) and IgM and the IgG avidity index.

Authors:  Eskild Petersen; Maria Victoria Borobio; Edward Guy; Oliver Liesenfeld; Valeria Meroni; Anne Naessens; Emma Spranzi; Philippe Thulliez
Journal:  J Clin Microbiol       Date:  2005-04       Impact factor: 5.948

7.  Reliability of immunoglobulin G antitoxoplasma avidity test and effects of treatment on avidity indexes of infants and pregnant women.

Authors:  Pierre Flori; Laetitia Tardy; Hugues Patural; Bahrie Bellete; Marie-Noëlle Varlet; Jamal Hafid; Hélène Raberin; Roger Tran Manh Sung
Journal:  Clin Diagn Lab Immunol       Date:  2004-07

8.  Toxoplasma seroconversion with negative or transient immunoglobulin M in pregnant women: myth or reality? A French multicenter retrospective study.

Authors:  H Fricker-Hidalgo; B Cimon; C Chemla; M L Darde; L Delhaes; C L'ollivier; N Godineau; S Houze; L Paris; D Quinio; F Robert-Gangneux; O Villard; I Villena; E Candolfi; H Pelloux
Journal:  J Clin Microbiol       Date:  2013-04-24       Impact factor: 5.948

9.  Usefulness of immunoblotting and Goldmann-Witmer coefficient for biological diagnosis of toxoplasmic retinochoroiditis.

Authors:  F Robert-Gangneux; P Binisti; D Antonetti; A Brezin; H Yera; J Dupouy-Camet
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2003-12-11       Impact factor: 3.267

10.  Use of an immunoglobulin G avidity assay based on recombinant antigens for diagnosis of primary Toxoplasma gondii infection during pregnancy.

Authors:  Elisa Beghetto; Wilma Buffolano; Andrea Spadoni; Mariassunta Del Pezzo; Manlio Di Cristina; Olga Minenkova; Eskild Petersen; Franco Felici; Nicola Gargano
Journal:  J Clin Microbiol       Date:  2003-12       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.